Veracyte Inc (Veracyte) is a diagnostics company that uses genomic technology to resolve diagnostic ambiguity. the company offers products such as Afirma, Percepta, Envisia, Prosigna, Lymphmark and Decipher. Its products are used in therapeutic areas such as thyroid, prostate, breast, bladder, lung cancers and interstitial lung diseases. Veracyte also provides vitro diagnostics (IVD) services including manufacturing, quality control, assay and process transfer, supply chain and other services to biopharmaceutical and diagnostics companies. The company operates in the US, France and Israel. Veracyte is headquartered in San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Veracyte Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Veracyte Inc Company Overview
- Veracyte Inc Company Snapshot
- Veracyte Inc Pipeline Products and Ongoing Clinical Trials Overview
- Veracyte Inc - Pipeline Analysis Overview
- Veracyte Inc - Key Facts
- Veracyte Inc - Major Products and Services
- Veracyte Inc Pipeline Products by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc Pipeline Products Overview
- Afirma - Risk of Recurrence
- Afirma - Risk of Recurrence Product Overview
- Afirma - Thyroid Cancer Staging/ Prognosis Test
- Afirma - Thyroid Cancer Staging/ Prognosis Test Product Overview
- Afirma Xpression Atlas - Pulmonology
- Afirma Xpression Atlas - Pulmonology Product Overview
- AI Based Liquid Biopsy Assay - Solid Tumors
- AI Based Liquid Biopsy Assay - Solid Tumors Product Overview
- BronchoGen Test
- BronchoGen Test Product Overview
- C2inform MRD Test
- C2inform MRD Test Product Overview
- Comprehensive Genomic Profiling Test
- Comprehensive Genomic Profiling Test Product Overview
- Decipher Prostate Biopsy Test
- Decipher Prostate Biopsy Test Product Overview
- Decipher Prostate Biopsy Test Clinical Trial
- Decipher Prostate RP Assay
- Decipher Prostate RP Assay Product Overview
- Diagnostic Assay - Renal Cancer
- Diagnostic Assay - Renal Cancer Product Overview
- Disease Diagnosis Device
- Disease Diagnosis Device Product Overview
- Envisia - Disease Progression Test
- Envisia - Disease Progression Test Product Overview
- Envisia - Rx Response Test
- Envisia - Rx Response Test Product Overview
- Envisia Genomic Classifier
- Envisia Genomic Classifier Product Overview
- Envisia IVD Test
- Envisia IVD Test Product Overview
- MRD Test - Muscle-Invasive Bladder Cancer
- MRD Test - Muscle-Invasive Bladder Cancer Product Overview
- nCounter Dx LymphMark Assay
- nCounter Dx LymphMark Assay Product Overview
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test Product Overview
- Percepta Atlas
- Percepta Atlas Product Overview
- Percepta Nasal Swab Test
- Percepta Nasal Swab Test Product Overview
- Percepta Nasal Swab Test Clinical Trial
- Prosigna NGS Test
- Prosigna NGS Test Product Overview
- Veracyte Inc - Key Competitors
- Veracyte Inc - Key Employees
- Veracyte Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Veracyte Inc, Recent Developments
- May 28, 2025: Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
- Apr 25, 2025: Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients With Metastatic Prostate Cancer
- Apr 22, 2025: Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at Aua Annual Meeting
- Apr 21, 2025: Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
- Mar 25, 2025: New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
- Feb 14, 2025: New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
- Feb 11, 2025: Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers To Be Presented at the 2025 Asco GU Symposium
- Oct 02, 2024: New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
- Sep 04, 2024: Veracyte Adds Brent Shafer and Tom Miller to Board of Directors
- May 06, 2024: 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Veracyte Inc Pipeline Products and Ongoing Clinical Trials Overview
- Veracyte Inc Pipeline Products by Equipment Type
- Veracyte Inc Pipeline Products by Indication
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc, Key Facts
- Veracyte Inc, Major Products and Services
- Veracyte Inc Number of Pipeline Products by Development Stage
- Veracyte Inc Pipeline Products Summary by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc Ongoing Clinical Trials Summary
- Afirma - Risk of Recurrence - Product Status
- Afirma - Risk of Recurrence - Product Description
- Afirma - Thyroid Cancer Staging/ Prognosis Test - Product Status
- Afirma - Thyroid Cancer Staging/ Prognosis Test - Product Description
- Afirma Xpression Atlas - Pulmonology - Product Status
- Afirma Xpression Atlas - Pulmonology - Product Description
- AI Based Liquid Biopsy Assay - Solid Tumors - Product Status
- AI Based Liquid Biopsy Assay - Solid Tumors - Product Description
- BronchoGen Test - Product Status
- BronchoGen Test - Product Description
- C2inform MRD Test - Product Status
- C2inform MRD Test - Product Description
- Comprehensive Genomic Profiling Test - Product Status
- Comprehensive Genomic Profiling Test - Product Description
- Decipher Prostate Biopsy Test - Product Status
- Decipher Prostate Biopsy Test - Product Description
- Decipher Prostate Biopsy Test - A Validation Study on the Impact of Decipher Testing on Treatment Recommendations in African-american and Non-african American Men with Prostate Cancer (VANDAAM Study)
- Decipher Prostate Biopsy Test - Genomics in Michigan to Adjust Outcomes in Prostate Cancer (G-MAJOR): A Randomized Multi-center Study for Men with Newly Diagnosed Favorable Risk Prostate Cancer
- Decipher Prostate Biopsy Test - STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomized Controlled Trial
- Decipher Prostate Biopsy Test - SURE-02_An Open Label, Single-arm, Phase 2 Study of Perioperative Pembrolizumab Plus Sacituzumab Govitecan, and Bladder-saving Approach, for Patients With Muscle-invasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy
- Decipher Prostate RP Assay - Product Status
- Decipher Prostate RP Assay - Product Description
- Diagnostic Assay - Renal Cancer - Product Status
- Diagnostic Assay - Renal Cancer - Product Description
- Disease Diagnosis Device - Product Status
- Disease Diagnosis Device - Product Description
- Envisia - Disease Progression Test - Product Status
- Envisia - Disease Progression Test - Product Description
- Envisia - Rx Response Test - Product Status
- Envisia - Rx Response Test - Product Description
- Envisia Genomic Classifier - Product Status
- Envisia Genomic Classifier - Product Description
- Envisia IVD Test - Product Status
- Envisia IVD Test - Product Description
- MRD Test - Muscle-Invasive Bladder Cancer - Product Status
- MRD Test - Muscle-Invasive Bladder Cancer - Product Description
- nCounter Dx LymphMark Assay - Product Status
- nCounter Dx LymphMark Assay - Product Description
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test - Product Status
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test - Product Description
- Percepta Atlas - Product Status
- Percepta Atlas - Product Description
- Percepta Nasal Swab Test - Product Status
- Percepta Nasal Swab Test - Product Description
- Percepta Nasal Swab Test - Clinical Utility of Management of Patients With CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier
- Prosigna NGS Test - Product Status
- Prosigna NGS Test - Product Description
- Veracyte Inc, Key Employees
- Veracyte Inc, Subsidiaries
- Glossary
- Veracyte Inc Pipeline Products by Equipment Type
- Veracyte Inc Pipeline Products by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lineage Cell Therapeutics Inc
- Baxter International Inc
- Lifelines Neurodiagnostic Systems Inc
- GeneThera Inc
- Atara Biotherapeutics Inc
